Diffuse Large B-Cell Lymphoma de novo | First line Chemotherapy Scheduled | R-CHOP Regimen | Chemotherapy cycle Quantity
Item
all patients must have a histologic or cytological diagnosis of de novo dlbcl and be scheduled to receive first line chemotherapy with r-chop given every 21 days (r-chop-21) within 6 weeks of their enrollment and for 6 cycles.
boolean
C0079744 (UMLS CUI [1,1])
C1515568 (UMLS CUI [1,2])
C1708063 (UMLS CUI [2,1])
C0392920 (UMLS CUI [2,2])
C0205539 (UMLS CUI [2,3])
C0393023 (UMLS CUI [3])
C1302181 (UMLS CUI [4,1])
C1265611 (UMLS CUI [4,2])
Age | Gender | Racial group | Faith | Ethnic group
Item
patients must be >=18 years of age, but there will be no discrimination based on gender, race, creed, or ethnic background.
boolean
C0001779 (UMLS CUI [1])
C0079399 (UMLS CUI [2])
C0034510 (UMLS CUI [3])
C0681191 (UMLS CUI [4])
C0015031 (UMLS CUI [5])
ECOG performance status
Item
patients must have an ecog performance status of 0-2.
boolean
C1520224 (UMLS CUI [1])
Informed Consent | Legal capacity
Item
patients must sign an informed consent, and be mentally responsible.
boolean
C0021430 (UMLS CUI [1])
C0683673 (UMLS CUI [2])
Complication Affecting Completion of clinical trial
Item
subjects with significant concurrent medical complications that in the judgment of the principal investigator(s) could affect the patient's ability to complete the planned trial, including the multiple imaging studies.
boolean
C0009566 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C2732579 (UMLS CUI [1,3])
Lymphoma Previous | Lymphoma, Follicular | Second Primary Cancers | Exception Basal cell carcinoma
Item
patients with history of prior lymphoma (e.g., follicular lymphoma) and/or second cancers other than basal cell carcinoma.
boolean
C0024299 (UMLS CUI [1,1])
C0205156 (UMLS CUI [1,2])
C0024301 (UMLS CUI [2])
C0751623 (UMLS CUI [3])
C1705847 (UMLS CUI [4,1])
C0007117 (UMLS CUI [4,2])
R-CHOP Regimen Time Interval Scheduled
Item
patients planned to be treated with r-chop-14 (i.e., r-chop given every 14 days) will be excluded (this should be extremely rare, if at all, since r-chop-21 is the standard treatment.
boolean
C0393023 (UMLS CUI [1,1])
C0872291 (UMLS CUI [1,2])
C0205539 (UMLS CUI [1,3])
Rituxan | X-Ray Therapy | Radioimmunotherapy
Item
patients who are scheduled to receive rituxan or any other therapy (e.g., xrt, radioimmunotherapy) as adjuvant therapy after completion of r-chop-21.
boolean
C0732355 (UMLS CUI [1])
C0043308 (UMLS CUI [2])
C0085101 (UMLS CUI [3])
Pregnancy
Item
pregnant women will be excluded.
boolean
C0032961 (UMLS CUI [1])
Childbearing Potential Contraceptive methods | Gender Contraceptive methods | Hormonal Contraception | Contraception, Barrier | Sexual Abstinence | Childbearing Potential Urine hCG pregnancy test
Item
women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) after study entry and for the duration of study participation. the effects of flt on the developing human fetus are unknown. should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. a screening urine human chorionic gonadtropin (hcg) (pregnancy test) will be administered in nuclear medicine to women of childbearing potential before each flt scan and pregnant women will be stopped from participating further in this study.
boolean
C3831118 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
C0079399 (UMLS CUI [2,1])
C0700589 (UMLS CUI [2,2])
C2985296 (UMLS CUI [3])
C0004764 (UMLS CUI [4])
C0036899 (UMLS CUI [5])
C3831118 (UMLS CUI [6,1])
C2188702 (UMLS CUI [6,2])